News & Updates

Treatment with the orexin receptor antagonist suvorexant does not appear to significantly reduce the incidence of delirium in hospitalized older adults when compared with placebo, according to data from a phase III study.

Treatment with mirtazapine to improve severe breathlessness in patients with chronic obstructive pulmonary disease (COPD), interstitial lung diseases (ILD), or both falls flat, with the use of the medication even associated with adverse reactions, as shown in a phase III study.

Antenatal exposure to metformin does not appear to harm neurodevelopmental outcomes in children, according to the results of a meta-analysis.

Treatment with liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX) improved overall survival (OS) and progression-free survival (PFS) in patients aged ≥65 years with metastatic pancreatic ductal adenocarcinoma (mPDAC) compared with gemcitabine plus nab-paclitaxel (Gem+NabP), according to a post hoc analysis of the phase III NAPOLI 3 trial presented at ESMO GI 2024.

New drug applications approved by US FDA as of 1-15 August 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Povidone iodine compares favourably with chlorhexidine gluconate in terms of reducing the incidence of surgical site infections (SSIs) after cardiac or abdominal surgical procedures, according to a study.

The use of a powder agent, either as monotherapy or in combination with other conventional therapy, appears to be safe and effective for endoscopic haemostasis in children with acute upper gastrointestinal (GI) bleeding (UGIB), according to real-world data from Singapore.